Gonadotropin Therapy for Hypogonadotropic Hypogonadism
hCG + FSH (and Pulsatile GnRH) - the Genuinely Successful Case in Male Fertility Pharmacology
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- hCG and menotropins/recombinant FSH are FDA-approved for inducing spermatogenesis in hypogonadotropic hypogonadism
Reference only. Not medical advice.
What can go wrong
Therapy is months-long, costly, and injection-intensive; gynecomastia and injection-site effects can occur, and ovarian-hyperstimulation analogs do not apply but careful dosing matters. Success is lower with very small baseline testes, prior undescended testes, or coexisting primary testicular damage. It treats secondary, not primary, hypogonadism - misapplying it to testicular failure wastes time and money. It is distinct from, and should not be conflated with, off-label clomiphene/enclomiphene marketing.
This is something to take to a clinician. The Atlas can tell you what is known about gonadotropin therapy for hypogonadotropic hypogonadism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Unlike most off-label hormonal tinkering, gonadotropin therapy for hypogonadotropic hypogonadism is a bona fide success story: men whose testes are intact but lack pituitary drive (congenital, e.g., Kallmann syndrome, or acquired) can be induced to produce sperm with hCG followed, if needed, by FSH - or with pulsatile GnRH when the defect is hypothalamic. Spermatogenesis is achieved in a majority over months, and this is an FDA-recognized indication, not a gray-market use.
The one place hormone therapy reliably builds sperm from scratch - and it is on-label.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
In hypogonadotropic hypogonadism the testis is capable but lacks pituitary stimulation. hCG acts as an LH analog on Leydig cells, driving the high intratesticular testosterone needed to start spermatogenesis; FSH (as hMG or recombinant FSH) then stimulates Sertoli cells to support sperm maturation. Where the defect is hypothalamic (no GnRH), a pulsatile GnRH infusion can restore the entire downstream axis physiologically. The result is genuine de novo sperm production, not merely a serum-testosterone bump.
What it does to fertility
This is a fertility-building therapy: hCG/FSH (or pulsatile GnRH) induce de novo spermatogenesis in men with secondary hypogonadism, the opposite of testosterone's suppressive effect.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Serum testosterone (target intratesticular support)
- FSH/LH context and inhibin B
- Testicular volume
- Serial semen analyses to detect sperm appearance
What people get wrong
Often saidAll hormone therapy for male fertility is unproven and off-label
ActuallyGonadotropin therapy for hypogonadotropic hypogonadism is FDA-recognized and reliably induces spermatogenesis in a majority - the clearest hormonal success in andrology.
Often saidTRT and gonadotropins do the same thing
ActuallyOpposite effects on fertility: TRT suppresses sperm production; hCG/FSH (and GnRH) induce it.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Unlike clomiphene/enclomiphene (off-label SERMs that depend on an intact, responsive HPG axis) gonadotropins directly supply the missing LH/FSH signal and have an FDA-recognized fertility indication in hypogonadotropic hypogonadism. Versus TRT - which suppresses fertility - gonadotropins build it. Pulsatile GnRH is the most physiologic option but requires a portable pump and an intact pituitary.
What we do not know
- Can priming with FSH before hCG improve outcomes in men with very small testes?
- What is the optimal regimen and duration to maximize live-birth rather than just sperm appearance?
- How early should fertility induction begin in adolescents with congenital hypogonadotropic hypogonadism?
At a glance
- Target patient
- Secondary (hypogonadotropic) hypogonadism - low LH/FSH, intact testes
- Core regimen
- hCG first; add FSH (hMG or recombinant) if no sperm after months
- Alternative
- Pulsatile GnRH pump for hypothalamic (e.g., Kallmann) cases
- Timeline
- Months; favorable testis size and no prior cryptorchidism predict success
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Gonadotropin Therapy for Hypogonadotropic Hypogonadism. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Gonadotropin induction of spermatogenesis in CHHMultiple cohorts (e.g., Liu et al.; Rastrelli/Maggi reviews)
hCG-based regimens, with FSH added as needed, induced sperm in a majority of men with hypogonadotropic hypogonadism, often within 6-24 months
Pulsatile GnRH versus gonadotropinsComparative studies
Both effective in hypothalamic CHH; predictors of success include larger baseline testicular volume and absence of prior cryptorchidism
Predictors of responseReviews
Baseline testicular volume and inhibin B/FSH context predict the likelihood and speed of achieving sperm in the ejaculate